KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Assets (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Current Assets data on record, last reported at $548.0 million in Q4 2025.

  • For Q4 2025, Current Assets fell 26.46% year-over-year to $548.0 million; the TTM value through Dec 2025 reached $548.0 million, down 26.46%, while the annual FY2025 figure was $548.0 million, 26.46% down from the prior year.
  • Current Assets reached $548.0 million in Q4 2025 per PCRX's latest filing, down from $562.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $866.0 million in Q4 2021 and bottomed at $376.1 million in Q1 2023.
  • Average Current Assets over 5 years is $620.8 million, with a median of $597.5 million recorded in 2024.
  • Peak YoY movement for Current Assets: surged 73.88% in 2021, then tumbled 43.61% in 2023.
  • A 5-year view of Current Assets shows it stood at $866.0 million in 2021, then crashed by 42.46% to $498.3 million in 2022, then rose by 2.34% to $510.0 million in 2023, then soared by 46.11% to $745.1 million in 2024, then dropped by 26.46% to $548.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $548.0 million in Q4 2025, $562.8 million in Q3 2025, and $745.6 million in Q2 2025.